US FDA To Require Patient Registry For Transmucosal Fentanyl Products
Executive Summary
In a series of REMS changes, FDA is finally embracing the "R-word" for transmucosal fentanyls that a "provocative" advisory committee member had suggested last year.
You may also be interested in...
Off-Label Use Of Transmucosal Fentanyl Creates Ethical, Practical Dilemma For US FDA
Advisory committee panelists divided on whether to modify REMS for TIRF products to reduce their wide-ranging off-label use.
Fentanyl REMS May Need Better Surveillance Methods Before Possible Modifications
Sponsors currently use sources such as spontaneous adverse event reports to assess whether REMS for immediate-release fentanyl products is achieving its purpose, although such methods are limited in their ability to portray a clear picture.
Xpovio Avoided Complete Response Letter Through Late-Cycle Submission Of BOSTON Data
After US FDA's Oncologic Drugs Advisory Committee voted to delay approval of Karyopharm's multiple myeloma drug Xpovio, the company submitted some data from the Phase III BOSTON trial, which prompted the FDA to award an accelerated approval for a narrower indication.